• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Direct oral anticoagulants for the prevention of thromboembolic complications of atrial fibrillation: The more you pay, the less you spend?

作者信息

Brunetti Natale Daniele, De Gennaro Luisa, Caldarola Pasquale, Gaglione Antonio, Di Biase Matteo

机构信息

Department of Medical & Surgical Sciences, University of Foggia, Foggia, Italy.

Cardiology Department, Ospedale San Paolo, Bari, Italy.

出版信息

Int J Cardiol. 2017 Aug 15;241:238-240. doi: 10.1016/j.ijcard.2017.03.059. Epub 2017 Mar 22.

DOI:10.1016/j.ijcard.2017.03.059
PMID:28363685
Abstract
摘要

相似文献

1
Direct oral anticoagulants for the prevention of thromboembolic complications of atrial fibrillation: The more you pay, the less you spend?直接口服抗凝剂用于预防心房颤动的血栓栓塞并发症：付出越多，花费越少？
Int J Cardiol. 2017 Aug 15;241:238-240. doi: 10.1016/j.ijcard.2017.03.059. Epub 2017 Mar 22.
2
[Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
Praxis (Bern 1994). 2014 Jun 18;103(13):785-6. doi: 10.1024/1661-8157/a001681.
3
[Prevention of thromboembolism in atrial fibrillation of non-valvular etiology].[非瓣膜性病因心房颤动中血栓栓塞的预防]
Ann Ital Med Int. 1996 Oct;11 Suppl 2:15S-17S.
4
Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.华法林用于心房颤动血栓栓塞的二级预防：生物利用度对成本和结局的影响。
Pharmacoeconomics. 2004;22(10):671-83. doi: 10.2165/00019053-200422100-00005.
5
[ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].[意大利心脏病学国家协会关于心房颤动血栓栓塞预防及新型口服抗凝剂作用的声明]
G Ital Cardiol (Rome). 2013 Apr;14(4):295-322. doi: 10.1714/1257.13889.
6
[ANMCO Position paper: Direct new oral anticoagulants for the prevention of thromboembolic complications in patients with atrial fibrillation: clinical scenarios and future perspectives].[意大利心脏病学和心血管病预防协会立场文件：新型口服直接抗凝剂用于预防心房颤动患者血栓栓塞并发症：临床情况与未来展望]
G Ital Cardiol (Rome). 2016 Sep;17(9 Suppl 1):3S-28. doi: 10.1714/2450.25666.
7
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.阿哌沙班与其他新型口服抗凝药预防心房颤动卒中的成本效益比较。
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.
8
[Anticoagulants in the prevention of complications in patients with atrial fibrillation].[抗凝剂在预防心房颤动患者并发症中的应用]
Kardiologiia. 2012;52(12):75-9.
9
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.心房颤动消融术前后口服抗凝药的使用：关于围手术期心房颤动消融术预防血栓栓塞的个体口服抗凝药使用的当前证据综述
J Cardiovasc Electrophysiol. 2014 Dec;25(12):1411-8. doi: 10.1111/jce.12546. Epub 2014 Oct 10.
10
Barriers to the use of warfarin: potential solutions.华法林使用的障碍：潜在解决方案。
J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e.

引用本文的文献

1
Budget impact analysis of PCSK9 inhibitors costs from a community payers' perspective in Apulia, Italy.从意大利普利亚地区社区支付者角度分析 PCSK9 抑制剂的成本预算影响。
Open Heart. 2019 Jul 29;6(2):e001018. doi: 10.1136/openhrt-2019-001018. eCollection 2019.
2
Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark.确定医疗保健部门的优先事项——以丹麦非瓣膜性心房颤动患者口服抗凝剂为例。
Clinicoecon Outcomes Res. 2017 Oct 13;9:617-627. doi: 10.2147/CEOR.S145813. eCollection 2017.